Market Place
Sourcing Support
Ex-Novartis, Chiasma leader joins Recordati Rare Diseases as CMO
25 Aug 2021 //
FIERCEBIOTECH
Chiasma Announces Submission of Marketing Authorization Application for MYCAPSSA
28 Jun 2021 //
GLOBENEWSWIRE
Amryt Pharma Announces update on Proposed Acquisition of Chiasma, Inc.
15 Jun 2021 //
GLOBENEWSWIRE
Chiasma to Present Encore and New Data from MPOWERED™ Phase 3
27 May 2021 //
GLOBENEWSWIRE
Chiasma to Present New Data at e-ECE and AACE Virtual Conferences
20 May 2021 //
GLOBENEWSWIRE
Chiasma Presents New Positive Data for MYCAPSSA from Phase 3 Trial MPOWERED™
23 Mar 2021 //
GLOBENEWSWIRE
Chiasma Presents Long-Term Safety and Efficacy Data the Open-Label Extension
22 Mar 2021 //
GLOBENEWSWIRE
Chiasma’s Octreotide Capsules Could Be Answer to Acromegaly Treatment Burdens
18 Sep 2020 //
BIOSPACE
Chiasma Announces U.S. Commercial Launch and Availability of MYCAPSSA®
31 Aug 2020 //
GLOBENEWSWIRE
Chiasma Announces Publication of Pivotal Data from the Ph3 CHIASMA
17 Aug 2020 //
GLOBENEWSWIRE
Chiasma Announces 48-Week Safety and Efficacy Data from the Open-Label Study
27 Jul 2020 //
GLOBENEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.